Quantifying the COVID19 infection risk due to droplet/aerosol inhalation.
Quantifying the COVID19 infection risk due to droplet/aerosol inhalation.
复制标题
量化因飞沫/气溶胶吸入而感染covid - 19的风险。
DOI：
10.1038/s41598-022-14862-y
复制
发表时间：
2022-07-01
影响因子：
4.6
通讯作者：
Tsubokura M
中科院分区：
文献类型：
--
作者：
Bale R;Iida A;Yamakawa M;Li C;Tsubokura M
剂量反应模型已被广泛用于量化COVID-19等空气传播疾病的感染风险。该模型已用于感染风险的房间平均分析和使用被动标量作为气溶胶运输代理的分析。然而，在液滴扩散的数值模拟中，还没有将其用于风险估计。在这项工作中，我们开发了一个使用剂量-反应模型评估液滴分散模拟中感染概率的框架。我们引入了一个版本的模型，该模型可以将SARS-CoV2变异株的高传播性和疫苗接种对评估感染概率的影响结合起来。利用该模型对语音过程中液滴的扩散进行了数值模拟，研究了液滴在空间和时间上的感染风险。通过分析环境风、湿度对感染风险的影响，并与基于被动标量的气溶胶运输风险评估进行比较，证明了液滴分散模拟在风险评估中的优势。
The dose-response model has been widely used for quantifying the risk of infection of airborne diseases like COVID-19. The model has been used in the room-average analysis of infection risk and analysis using passive scalars as a proxy for aerosol transport. However, it has not been employed for risk estimation in numerical simulations of droplet dispersion. In this work, we develop a framework for the evaluation of the probability of infection in droplet dispersion simulations using the dose-response model. We introduce a version of the model that can incorporate the higher transmissibility of variant strains of SARS-CoV2 and the effect of vaccination in evaluating the probability of infection. Numerical simulations of droplet dispersion during speech are carried out to investigate the infection risk over space and time using the model. The advantage of droplet dispersion simulations for risk evaluation is demonstrated through the analysis of the effect of ambient wind, humidity on infection risk, and through a comparison with risk evaluation based on passive scalars as a proxy for aerosol transport.
登录
查看更多内容
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
5.8
作者：
Gupta, Jitendra K.;Lin, Chao-Hsin;Chen, Qingyan
通讯作者：
Chen, Qingyan
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
4.5
作者：
Chao, C. Y. H.;Wan, M. P.;Katoshevski, D.
通讯作者：
Katoshevski, D.